Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology Inc.

Jefferies analyst Roger Song maintained a Buy rating on Kura Oncology today and set a price target of $28.00. According to TipRanks, Song is a 2-st...

Kura Oncology (KURA) Gets a Buy from Jefferies

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Kura Oncology, with a price target of $28.00. Darout covers the H...

Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)

Barclays analyst Etzer Darout maintained a Buy rating on Kura Oncology today and set a price target of $28.00. According to TipRanks, Darout is a 5...

Barclays Remains a Buy on Kura Oncology (KURA)

By the end of this month, two pharmaceutical firms are set to receive a decision on their drug approval applications from the U.S. Food and Drug Ad...

FDA Calendar: These Are the Upcoming FDA Drug Approvals 

In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Kura Oncology, with a price target of $38.00. Driscoll covers t...

Wedbush Remains a Buy on Kura Oncology (KURA)

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Kura Oncology. The company’s shares closed yesterday at $10.68...

TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)

Kura Oncology ( ($KURA) ) just unveiled an announcement. On November 13, 2025, Kura Oncology and Kyowa Kirin announced the FDA’s full approval of K...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KURA	$10.22	-2.29%	1.48M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KURA	$10.22	-2.3%	1.48M
3
4
5
6

KURA

KURA

Dividend Overview

Get Kura Oncology Inc. Data in Excel

Get Kura Oncology Inc. Data in Excel